Study: 66 Percent of Men with Positive MRI for Prostate Cancer Had Normal PSA Levels
Two-thirds of men with a positive screening MRI for prostate cancer had PSA levels below 3 ng/mL and 91 percent of these men had clinically significant prostate cancer, according to newly published research.
New Research Shows Consequences of Delayed Diagnosis in Mammography Screening
Primary diagnostic delays in mammography screening led to a greater than 10 percent higher incidence of lymph node metastasis with invasive breast cancer in comparison to women without a primary diagnostic delay, according to new research out of the Netherlands.
Emerging Innovations in Molecular Imaging
In interviews at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) conference, researchers discussed the potential impact of ultra-high resolution brain positron emission tomography (PET) as well as emerging PET radiotracers for detecting coronary artery disease in obese patients and diagnosing clear cell renal cell carcinoma.
Is Pre-Imaging Biopsy Necessary for Prostate Cancer Staging in Elderly Patients?
For patients 80 years of age or older that have a PSA level at 20 ng/mL or higher, PSMA PET/CT has a high likelihood of success in diagnosing and staging prostate cancer regardless of pre-imaging biopsy use, according to newly published research.
In an analysis of patients with intraprostatic/prostate bed findings of biochemical prostate cancer recurrence, the use of 18F-DCFPyL PET/CT led to an 82.3 percent cancer detection rate in comparison to 80 percent for multiparametric MRI, according to research presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
Study Reveals Tradeoffs Between Contrast-Enhanced Mammography and MRI for Supplemental Screening
In a new study comparing standard breast MRI, abbreviated breast MRI and contrast-enhanced mammography in supplemental breast cancer screening, researchers found that MRI offered a greater than 14 percent higher cancer detection rate and a nearly 39 percent higher sensitivity rate than CEM.
Viz.ai Gets FDA Nod for Hypertrophic Cardiomyopathy Module
The De Novo approval for Viz HCM, which assesses electrocardiograms with artificial intelligence (AI) to identify possible cases of hypertrophic cardiomyopathy (HCM), is the 12th FDA clearance of algorithms on the Viz.ai Platform.
In the first episode of a three-part series, Anand Narayan, M.D., Ph.D., and Amy Patel, M.D., discuss recently issued updates to breast cancer screening recommendations from the American College of Radiology and the United States Preventive Services Task Force and potential implications for health equity.
In a recent study examining neuroimaging biomarkers of Alzheimer’s disease, researchers found that neocortical tau pathology exhibited the strongest association with cognitive decline and the use of tau positron emission tomography (tau-PET) provided the best prognostic value of all neuroimaging modalities in this patient population.
Study: Abbreviated Non-Contrast MRI May Facilitate Early Detection of Prostate Cancer
The use of non-contrast, biparametric MRI (bpMRI) for prostate cancer screening regardless of PSA values detected more clinically significant cases of prostate cancer than reserving bpMRI for patients with elevated PSA levels, according to preliminary findings from an ongoing prospective, randomized study.